Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273050 | 0.89 | SRC (0.57) | SRCNPC1DHFRHSP90AA1HSP90AB1 | |
| SCHEMBL4264699 | 0.85 | SRC (0.70) | SRCHSP90AA1HSP90AB1 | |
| SCHEMBL15095302 | 0.85 | SRC (0.58) | SRCADORA2AADORA1 | |
| SCHEMBL13609478 | 0.77 | SRC (0.69) | SRCADORA2AADORA1 | |
| SCHEMBL4270715 | 0.73 | SRC (0.57) | SRCHSP90AA1HSP90AB1 | |
| SCHEMBL13609499 | 0.72 | SRC (0.59) | SRCNPC1DHFRHSP90AA1HSP90AB1 | |
| SCHEMBL4270512 | 0.72 | SRC (0.59) | SRCDHFRHSP90AA1 | |
| SCHEMBL4275174 | 0.70 | SRC (1.00) | SRC | |
| SCHEMBL4266529 | 0.70 | SRC (0.79) | SRCHSP90AA1HSP90AB1 | |
| SCHEMBL4264301 | 0.70 | SRC (0.66) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809614-B1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8481536-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2543376-A1 | Benzotriazine inhibitors of kinases | Targegen, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | TARGEGEN, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456176-B2 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294796-A1 | BENZOTRIAZINE INHIBITORS OF KINASES | SRC, CAMK4, CAMK2G | SRC 1/4885NPC1 3968/4885DHFR 1676/4885 |
| US-20090275569-A1 | Benzotriazine Inhibitors of Kinases | SRC, CAMK4, CAMK2G | SRC 1/4885NPC1 3968/4885DHFR 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.